A detailed history of Black Rock Inc. transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 6,620,004 shares of VERV stock, worth $37.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,620,004
Previous 5,373,177 23.2%
Holding current value
$37.1 Million
Previous $71.4 Million 54.73%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$4.76 - $12.79 $5.93 Million - $15.9 Million
1,246,827 Added 23.2%
6,620,004 $32.3 Million
Q1 2024

May 10, 2024

BUY
$10.81 - $17.96 $10.1 Million - $16.8 Million
937,696 Added 21.14%
5,373,177 $71.4 Million
Q4 2023

Feb 13, 2024

BUY
$8.84 - $18.7 $3.86 Million - $8.17 Million
437,082 Added 10.93%
4,435,481 $61.8 Million
Q3 2023

Nov 13, 2023

BUY
$11.42 - $20.82 $1.73 Million - $3.16 Million
151,696 Added 3.94%
3,998,399 $53 Million
Q2 2023

Aug 11, 2023

BUY
$13.34 - $19.9 $4 Million - $5.97 Million
300,218 Added 8.47%
3,846,703 $72.1 Million
Q1 2023

May 12, 2023

SELL
$14.3 - $24.01 $680,522 - $1.14 Million
-47,589 Reduced 1.32%
3,546,485 $51.1 Million
Q4 2022

Feb 13, 2023

BUY
$17.85 - $40.7 $3.89 Million - $8.87 Million
217,864 Added 6.45%
3,594,074 $69.5 Million
Q3 2022

Nov 14, 2022

BUY
$15.63 - $41.49 $12.4 Million - $32.9 Million
792,139 Added 30.65%
3,376,210 $116 Million
Q2 2022

Aug 12, 2022

BUY
$11.14 - $23.17 $4.74 Million - $9.86 Million
425,509 Added 19.71%
2,584,071 $39.5 Million
Q1 2022

May 12, 2022

BUY
$20.92 - $39.36 $19.1 Million - $36 Million
915,090 Added 73.59%
2,158,562 $49.3 Million
Q4 2021

Feb 10, 2022

BUY
$31.94 - $54.82 $9.55 Million - $16.4 Million
299,015 Added 31.66%
1,243,472 $45.8 Million
Q3 2021

Nov 09, 2021

BUY
$46.0 - $73.99 $19.1 Million - $30.7 Million
414,533 Added 78.22%
944,457 $44.4 Million
Q2 2021

Aug 11, 2021

BUY
$31.92 - $60.25 $16.9 Million - $31.9 Million
529,924 New
529,924 $31.9 Million

Others Institutions Holding VERV

About Verve Therapeutics, Inc.


  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $336M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.